News-Medical.Net on MSN11h
Natural product derivative demonstrates promising therapeutic potential for psoriasis
Announcing a new publication for Acta Materia Medica journal. Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase ...
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...
Healio1d
Addressing skin disease with medications alone is ‘not enough,’ diet also brings benefits
Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...
Medscape5d
Anti–IL-23 Therapy Might Emerge as Best Biologic in Psoriasis if Used Early and at High Doses
In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...
MedPage Today on MSN5d
Newer Biologics Tied to Fewer Infections for Older Patients With Psoriatic Disease
IL-23, and IL-17 were associated with a lower rate of serious infections among older adults with psoriatic disease, a ...
News-Medical.Net on MSN6d
Mediterranean diet shows promise in easing psoriasis, acne, and hidradenitis suppurativa
A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...
Medscape8d
Significant Improvement in Psoriasis Observed With Novel Oral Drug Icotrokinra, in Phase 3 Trial
Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...
European Medical Journal5d
Psoriasis Treatment Study Confirms Biosimilar Effectiveness
Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...
Healthline12d
What’s the Connection Between Psoriasis and Liver Disease?
Some evidence suggests a higher risk of liver disease with psoriasis. Certain psoriasis treatments can cause liver toxicity, but the two conditions also share common risk factors, which may ...
Nasdaq1d
Can-Fite BioPharma Initiates Pivotal Phase 3 Study for Oral Drug Piclidenoson in Psoriasis Treatment
Can-Fite BioPharma initiates pivotal Phase 3 study for psoriasis treatment using oral drug Piclidenoson, targeting moderate to severe cases. Can-Fite BioPharma Ltd. announced the initiation of a ...
Morningstar1d
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
The Company’s lead drug candidate, Piclidenoson reported topline results in a Phase III trial for psoriasis and commenced a pivotal Phase III trial. Can-Fite’s liver drug, Namodenoson ...